Sinusway (832147)

  https://cordis.europa.eu/project/id/832147

  Horizon 2020 (2014-2020)

  Sinusway- a revolutionary single-use endoscope device for treatment of severe sinuses infection (Sinusitis)

  SME instrument (EIC-SMEInst-2018-2020)

  asthma  ·  anatomy and morphology  ·  surgery  ·  otorhinolaryngology  ·  ergonomics

  2018-11-01 Start Date (YY-MM-DD)

  2019-02-28 End Date (YY-MM-DD)

  € 71,429 Total Cost

  Description

Rhinosinusitis (RS) (better known as sinusitis) is a severe infection caused when the tiny air pockets around the bones of the nose are filled with germs or fluids. Sinusitis affects more than 80 million people in Europe and 803 million around the world, making it one of the most common health problems worldwide. Sinusitis sufferers carry a huge burden of symptoms, including challenging breathing, headaches, facial pain, nasal congestions, fever and disrupted sleep all of which drastically affects their quality of life. Since thin sinus walls share a border with the surrounding tissue, sinus infection can spread beyond the border of sinuses and cause major complications to eyes, brain and even cause asthma and bone infections. Hence, proper diagnosis and management of sinusitis is essential to prevent the risk of complications. However, current drawbacks of tools available to physicians make diagnosis and management of sinusitis very difficult. Sinusway is a novel lightweight single use endoscope for patients suffering from sinusitis. Sinusway is the first one that allows the tip of the endoscope to turn sharply into lumens in the sinus and then advance in the direction of the angulation which was set, beyond the point of angulation and independently from it. This allows to reach more than 90% of the sinus area. Using an intuitive easy-to-use ergonomics, ENT physicians have full control over the direction of the advancement of the endoscope, without the need of the support from the anatomy to do so. As such, Sinusway represents a revolutionary solution to a global market expected to grow to €20.86 billion by 2022.

  Complicit Organisations

1 Israeli organisation participates in Sinusway.